Migraine

A clinical-stage neuroscience-focused biopharmaceutical company has received new international patents related to an investigational neuroactive pherine nasal spray to potentially treat individuals with migraine.

SAN DIEGO — Patients who used two or more triptans for migraine faced more acute treatment, more emergency-related hospital visits and higher medical costs compared with those who used one, data show.

SAN DIEGO — Treating migraine with a novel formulation of dihydroergotamine powder was linked to favorable outcomes including significant headache pain reduction at 48 hours post dose that was extended to 12 months.

SAN DIEGO — In a small cohort of young people, use of gepants to treat headache led to some therapeutic benefit and led to few adverse events, according to a poster from the American Headache Society Annual Scientific Meeting.

SAN DIEGO — A wearable remote electrical neuromodulation device provided consistent efficacy and clinically meaningful benefit to those with migraine, according to a poster presentation at the American Headache Society Annual Scientific Meeting.

SAN DIEGO — For younger people with migraine, lidocaine injections were linked to better outcomes compared with saline injections, according to a speaker at the American Headache Society Annual Scientific Meeting.

SAN DIEGO — Patients with migraine who received daytime psilocybin experienced reduced REM sleep, with effects lasting beyond the day of administration, according to a poster at the American Headache Society Annual Scientific Meeting.

SAN DIEGO — A novel, oral therapeutic for treatment of migraine was safe and well-tolerated in single ascending doses in a cohort of healthy adults, according to a speaker at the American Headache Society Annual Scientific Meeting.